Novel imaging agent targets pancreatic cancer

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

MabVax Therapeutic Holdings, in collaboration with the Memorial Sloan Kettering Cancer Center (MSKCC), is presenting an investigational agent for imaging pancreatic cancer and aiding pancreatic tumor resection, MabVax announced Nov. 19.

The San Diego-based pharmaceutical company has developed the agent, called HuMab 5B1, to carry two separate imaging agents conjugated with a tumor-seeking antibody to improve tumor targeting and surgical removal.

"With five-year survival rates in pancreatic cancer of only 5 percent and more than half of all patients initially diagnosed already having metastatic disease, the difficulties in identifying distant metastases that often go undetected as well as problems defining tumor margins during resection are both major concerns that affect outcomes for pancreatic cancer patients,” said MabVax president and CEO J. David Hansen, in a press release. “This study showed favorable results for the dual labeled antibody in detecting human pancreatic cancer cells in the animal model."

Researchers used both PET and near-infrared imaging, both of which showed strong uptake of the drug, and fluorescent tagging improved image-guided surgical resection of targeted tissues. The HuMab 5B1 antibody is also being groomed for use in colon cancer research.

The human antibody is derived from cancer vaccine research conducted at MSKCC in New York. A dual phase I trial for HuMab 5B1 is set for sometime in 2015 at the institution.


 

Kathy Mahdoubi

Related Content

Radiotracers on FDA’s fast track exceed performance of already approved tau-detecting agent
PET scans unlock clues that could help prevent epilepsy induced by head injuries
Dementia cases are about to skyrocket—how will this affect imaging demand?
Experts update AUC for amyloid, tau PET imaging for first time in more than a decade
Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner

Around the web

Radiology Business
Ultrasound-first strategy for noncalcified lesions in DBT proves cost-effective

Jessica Porembka, MD, of the breast imaging division at University of Texas Southwestern Medical Center, said an ultrasound-first strategy for these lesions in DBT is cost-effective and improves efficiency. 

Radiology Business
Concerns about private equity's growing influence in radiology

Melissa Davis, MD, vice chair of medical informatics and associate professor at Yale University’s Department of Radiology and Biomedical Imaging, shares her findings from research on private equity market penetration.

 

Radiology Business
AI can help radiology standardize image exam data labeling

To fully leverage today's radiology IT systems, standardization is a necessity. Steve Rankin, chief strategy officer for Enlitic, explains how artificial intelligence can help.